Senzime's board member Ulf Lindskog has passed away
“Ulf was a very successful entrepreneur who among other things built up Sweden's largest private ambulance business with over 500 employees. His commitment to Senzime, both as a board member and one of the company's largest shareholders, has been very important for the company's development. Ulf had a unique ability to inspire talented leaders and people around him and will be deeply missed by the board and the employees at Senzime. Our thoughts go to his family”, says Philip Siberg, Chairman of the Board.
The work of completing the existing board will start shortly.
For further information, please contact:
Philip Siberg, Chairman of the Board
Tel: +46 (0) 70 790 6734, email: email@example.com
TO THE EDITORS
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, firstname.lastname@example.org, is Certified Adviser for Senzime. www.senzime.com